Neurobiological Technologies IncOver The Counter Market:NTII
- LAST PRICE0.0000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.0000
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Neurobiological Technologies Inc | 30.0 | 0.0x | --- |
Synovics Pharmaceuticals Inc | 3.0K | 0.0x | --- |
Gelesis Holdings Inc | 1.5M | 0.0x | --- |
Sunshine Biopharma Inc | 944.8K | 0.0x | --- |
cbdMD Inc | 2.7M | 0.0x | --- |
Cyanotech Corp | 2.1M | -0.4x | --- |
Company Information
Neurobiological Technologies, Inc. (NTI), was previously focused on developing investigational drugs to treat human diseases. On October 27, 2009, the Company’s stockholders approved the dissolution of the Company pursuant to a plan of complete liquidation and dissolution earlier approved by its board of directors on August 27, 2009 (the Plan of Dissolution). As a Company in dissolution, NTI was not allowed to carry on any business except for the purpose of winding down the business and affairs of the Company. On December 17, 2009, the Company filed a certificate of dissolution with the Secretary of State of the State of Delaware (the Certificate of Dissolution). As of June 30, 2010, NTI retains an interest in an investigational drug called XERECEPT, which is a synthetic preparation of Corticotropin-Releasing Factor, a natural human peptide. XERECEPT is being developed by Celtic Pharma as a treatment for swelling around brain tumors and other cancer indications.
Contact Information
- Headquarters
- 2010 Crow Canyon Pl Ste 100SAN RAMON, CA, United States 94583-1344
- Phone
- 925-359-3247
- Fax
- 302-636-5454
Executives
- Acting Chief Executive and Financial Officer, Director
- Matthew Loar
- Director
- William Fletcher
- Director
- John Stuppin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $30.00 |
|---|---|
Revenue (TTM) | $25.3M |
Shares Outstanding | 27.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $0.69 |
Book Value | $0.87 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.0 |
Price/Cash Flow (TTM) | 0.0x |
Operating Margin | 72.21% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
